Search Results for: FSD Pharma

FSD Pharma Takes Steps To Mitigate The Impact Of COVID-19 On Its Cannabis Production Facility In Cobourg, Ontario

CANADA: FSD Pharma Inc. today announced that it has taken steps to mitigate the impact of the novel coronavirus SARS-CoV-2 pandemic on its wholly-owned subsidiary, FV Pharma Inc., a licensed producer under Canada’s Cannabis Act and Regulations, and its facility in Cobourg, Ontario. The Company’s actions are aligned with evolving guidance from provincial and local Read the full article…

FSD Pharma To Begin Trading On The NASDAQ Capital Market Under Symbol ‘HUGE’ January 9, 2020

CANADA: FSD Pharma Inc. today announced that its Class B Subordinate Voting Shares (the “Shares”) have been approved for listing on the NASDAQ Capital Market under the symbol ‘HUGE’. Trading on the NASDAQ is expected to commence at market open on Thursday, January 9, 2020. The Company’s Shares will continue to be listed on the Canadian Read the full article…

FSD Pharma Appoints Former Member Of U.S. Congress To Its Board of Directors, Announces Share Consolidation

CANADA: FSD Pharma announced the appointment of former U.S. congressman Stephen Buyer to the Company’s Board of Directors. The Company also announced that it will complete a consolidation of its class A multiple voting shares and its class B subordinate voting shares each on a 1 to 201 basis. “In welcoming Steve Buyer to the Read the full article…

FSD Pharma Receives Cannabis Sales License From Health Canada

CANADA: FSD Pharma Inc. announced that its wholly-owned subsidiary FV Pharma Inc. has received its Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The license went into effect on April 18, 2019. The license allows the current FSD facility to supply and sell cannabis products. The company anticipates receiving the amended sales license that will include the sale of dried and fresh cannabis flower in Read the full article…

FSD Pharma To Establish Presence In Canada’s Insurance Regimes

Signs agreement focusing on exploring insurance coverage for medical cannabis Canada wide CANADA: FSD Pharma Inc. announced the signing of a consulting agreement with Joseph L. Romano, a well-respected lawyer with a strong track-record in personal injury law. Mr. Romano has been working with medical cannabis since 2006, assisting people coping with chronic pain to have Read the full article…

Investors That Purchased FSD Pharma Securities May Have An Opportunity To Recover Their Financial Losses.

CANADA: Morganti & Co., P.C., a cross border shareholder’s rights law firm, has commenced a shareholder class action lawsuit against FSD Pharma Inc. for publishing investor documents containing misrepresentations of material fact about the status of its joint venture with Auxly Cannabis Group Inc. between September 29, 2018, and January 7 or February 6, 2019. The shareholders Read the full article…

FSD Pharma Announces Strategic Investment In Toronto’s Huge Shops

FSD Pharma Announces Strategic Investment in Huge Shops CANADA: FSD Pharma has completed a strategic investment of $1.3 million or just under 9.9% in Huge Shops, a Toronto-based cannabis retailer. Huge Shops has a strategic alliance with Chairman’s Brands, parent company of Coffee Time, a well-established operator of retail coffee shops with more than 75 locations in Read the full article…

FSD Pharma Achieves Over 4 Billion Shares Traded In First 6 Months

CANADA:  FSD Pharma announced today that the Company has traded over four Billion Class B subordinate voting shares in its first six months of trading on the Canadian Securities Exchange. During the period of May 29, 2018 to November 29, 2018, the Company traded exactly 4,041,346,300 Class B subordinate voting shares on the CSE. This Read the full article…

FSD Pharma Appoints Top GW Pharmaceuticals Executive As Chief Executive Officer

Management addition comes as FSD accelerates specialty cannabinoid pharmaceutical global expansion strategy CANADA:  FSD Pharma announced today the appointment of Rupert Haynes as Chief Executive Officer. Mr. Haynes is a highly accomplished healthcare executive with nearly three decades of global pharmaceutical experience having most recently held the position of Head of Global Marketing at GW Pharmaceuticals Read the full article…

FSD Pharma Announces Launch of IBS Clinical Study

CANADA: FSD Pharma has announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic R&D partner, SciCann Therapeutics. The study is designed to test the safety and efficacy of SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome (IBS) patients. This study follows the previously reported efficacy Read the full article…